Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M S Springer

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
European Journal of Pharmacology|December 6, 2000
The CXCR4 agonist ligand stromal derived factor-1 maintains high affinity for receptors in both Galpha(i)-coupled and uncoupled statesJ Di Salvo, G E Koch, K E Johnson, et al.
Bioorganic & Medicinal Chemistry Letters|September 11, 2001
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: synthesis and structure-activity relationships for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N-(benzyloxycarbonyl)amino)piperidin-1-yl)butanesP E Finke, B Oates, S G Mills, et al.
Bioorganic & Medicinal Chemistry Letters|November 27, 2001
Combinatorial synthesis of CCR5 antagonistsC A Willoughby, S C Berk, K G Rosauer, et al.
Journal of Virology|March 27, 2001
CCR5, CXCR4, and CD4 are clustered and closely apposed on microvilli of human macrophages and T cellsI I Singer, S Scott, D W Kawka, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 1, 1997
Blockade of the voltage-gated potassium channel Kv1.3 inhibits immune responses in vivoG C Koo, J T Blake, A Talento, et al.
Bioorganic & Medicinal Chemistry Letters|October 10, 2001
1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activityJ J Hale, R J Budhu, E B Holson, et al.
Bioorganic & Medicinal Chemistry Letters|February 24, 2001
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanesP E Finke, L C Meurer, B Oates, et al.
Bioorganic & Medicinal Chemistry Letters|November 27, 2001
Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infectionD Kim, L Wang, C G Caldwell, et al.
Bioorganic & Medicinal Chemistry Letters|November 27, 2001
Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infectionD Kim, L Wang, C G Caldwell, et al.
Bioorganic & Medicinal Chemistry Letters|February 24, 2001
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. part 1: discovery and initial structure-activity relationships for 1 -amino-2-phenyl-4-(piperidin-1-yl)butanesC P Dorn, P E Finke, B Oates, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
European Journal of Pharmacology|December 6, 2000
The CXCR4 agonist ligand stromal derived factor-1 maintains high affinity for receptors in both Galpha(i)-coupled and uncoupled statesJ Di Salvo, G E Koch, K E Johnson, et al.
Bioorganic & Medicinal Chemistry Letters|September 11, 2001
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: synthesis and structure-activity relationships for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N-(benzyloxycarbonyl)amino)piperidin-1-yl)butanesP E Finke, B Oates, S G Mills, et al.
Bioorganic & Medicinal Chemistry Letters|November 27, 2001
Combinatorial synthesis of CCR5 antagonistsC A Willoughby, S C Berk, K G Rosauer, et al.
Journal of Virology|March 27, 2001
CCR5, CXCR4, and CD4 are clustered and closely apposed on microvilli of human macrophages and T cellsI I Singer, S Scott, D W Kawka, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 1, 1997
Blockade of the voltage-gated potassium channel Kv1.3 inhibits immune responses in vivoG C Koo, J T Blake, A Talento, et al.
Bioorganic & Medicinal Chemistry Letters|October 10, 2001
1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activityJ J Hale, R J Budhu, E B Holson, et al.
Bioorganic & Medicinal Chemistry Letters|February 24, 2001
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanesP E Finke, L C Meurer, B Oates, et al.
Bioorganic & Medicinal Chemistry Letters|November 27, 2001
Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infectionD Kim, L Wang, C G Caldwell, et al.
Bioorganic & Medicinal Chemistry Letters|November 27, 2001
Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infectionD Kim, L Wang, C G Caldwell, et al.
Bioorganic & Medicinal Chemistry Letters|February 24, 2001
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. part 1: discovery and initial structure-activity relationships for 1 -amino-2-phenyl-4-(piperidin-1-yl)butanesC P Dorn, P E Finke, B Oates, et al.
Pageof 8